{{Rsnum
|rsid=223899
|Gene=CCL17
|Chromosome=16
|position=57410664
|Orientation=minus
|GMAF=0.2553
|Gene_s=CCL17
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;C)
|geno3=(C;C)
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;C)
| geno3=(C;C)
| CEU | 3.5 | 35.4 | 61.1
| HCB | 16.1 | 44.5 | 39.4
| JPT | 26.5 | 48.7 | 24.8
| YRI | 0.0 | 2.7 | 97.3
| ASW | 0.0 | 8.8 | 91.2
| CHB | 16.1 | 44.5 | 39.4
| CHD | 13.8 | 45.9 | 40.4
| GIH | 5.0 | 37.6 | 57.4
| LWK | 0.0 | 0.0 | 0.0
| MEX | 13.8 | 55.2 | 31.0
| MKK | 0.0 | 9.0 | 91.0
| TSI | 0.0 | 33.3 | 66.7
| HapMapRevision=28
}}{{PMID Auto
|PMID=23920401
|Title=Genetic variants in nuclear factor-kappa B binding sites are associated with clinical outcomes in prostate cancer patients
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Illumina Human 1M}}